Variant [Creutzfeldt Jakob Disease[/diseases/[creutzfeldt-jakob-disease[/diseases/[creutzfeldt-jakob-disease[/diseases/[creutzfeldt-jakob-disease[/diseases/[creutzfeldt-jakob-disease--TEMP--/diseases)--FIX-- (vCJD) is a progressive neurodegenerative disorder characterized affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.
Variant Creutzfeldt-Jakob Disease (vCJD) is a fatal, transmissible spongiform encephalopathy (TSE) first identified in the United Kingdom in 1996, caused by the same prion
strain responsible for bovine spongiform encephalopathy (BSE, "mad cow disease") in cattle[4]. Unlike
classical Creutzfeldt-Jakob Disease (CJD), vCJD predominantly affects younger individuals (median age ~26 years at onset[2]), presents
initially with psychiatric symptoms rather than cognitive decline, and is characterized by distinct neuropathological features including widespread "florid" amyloid plaques
surrounded by spongiform change.
vCJD results from exposure to the BSE prion — primarily through consumption of BSE-contaminated beef products during the 1980s–1990s epidemic in the UK. Since its discovery, 233
cases have been reported worldwide, with the vast majority (178[19]) in the United Kingdom. The incidence peaked in 2000 and has declined sharply, though concerns persist about
potential secondary transmission through blood transfusion, surgical instruments, and the possibility of prolonged incubation periods in individuals with non-MM genotypes at the
PRNP gene codon 129 polymorphism.
vCJD is invariably fatal, with a median survival of approximately 14 months[2] from symptom onset. There is no effective treatment, and diagnosis is confirmed only by [neuropathological
examination[/diagnostics/[neuropathological-examination[/diagnostics/[neuropathological-examination[/diagnostics/[neuropathological-examination[/diagnostics/[neuropathological-examination--TEMP--/diagnostics)--FIX--, though emerging blood-based assays show promise for presymptomatic detection.
vCJD was first recognized as a distinct clinical entity in 1996 when the United Kingdom's National CJD Surveillance Unit identified a cluster of patients with a previously
uncharacterized progressive neuropsychiatric disorder[2]. Subsequent epidemiological and laboratory investigations established the link between vCJD and exposure to BSE-contaminated food products. The BSE epidemic
in cattle peaked in the UK in 1992-1993, and the first cases of vCJD appeared approximately 10 years later, consistent with a long incubation period.
- Total cases worldwide[19]: 233 (as of 2024)
- United Kingdom: 178[19] cases (76% of all cases)
- France: 29 cases
- Other countries: Spain (5), Ireland (4), United States (4), Netherlands (3), Italy (3), Portugal (2), Canada (2), Japan (1), Taiwan (1), Saudi Arabia (1)
- Peak year[19]: 2000 (28 cases in UK)
- Recent cases: Fewer than 1 per year globally since 2012
- Age at onset: Median ~26 years[2] (range 12–74); significantly younger than classical CJD (median ~67 years)
- Sex: Roughly equal distribution (slight male predominance in some series)
- Genetic susceptibility: All definite clinical cases to date have been methionine homozygous (MM) at PRNP codon 129[2]. However, preclinical prion infection has been detected in appendix tissue of individuals with MV genotype, raising concern about future cases with potentially longer incubation periods.
- Estimated at ~10–15 years[2] from dietary exposure, based on the temporal relationship between the UK BSE epidemic peak (1989–1993) and the vCJD epidemic peak (1999–2000).
- Potentially much longer for non-MM genotypes — one confirmed case in an MV heterozygote in 2016 raised the possibility of a "second wave" with incubation periods >20 years.
¶ Etiology and Transmission
vCJD was caused by cross-species transmission of the BSE prion[4] from cattle to humans through the food chain. The UK BSE epidemic
(1986–2001) exposed millions to potentially infected beef products before the implementation of effective control measures:
- 1986: BSE first identified in UK cattle
- 1988: Ruminant feed ban (prohibiting feeding of ruminant-derived meat-and-bone meal to ruminants)
- 1989: Specified bovine offal (SBO) ban — removal of high-risk tissues from the food chain
- 1996: vCJD first described; UK government acknowledged probable link to BSE
- 2001: EU-wide BSE testing of cattle at slaughter
- Dietary (primary): Consumption of BSE-contaminated beef, particularly mechanically recovered meat and products containing CNS tissue
- Blood transfusion: Four cases of vCJD transmitted by transfusion[13] of non-leukodepleted red blood cells from presymptomatic donors in the UK
- Theoretical risks: Surgical instruments (prions resist standard sterilization), organ/tissue transplantation, contaminated growth hormone (this caused iatrogenic CJD, not vCJD)
¶ Species Barrier and Genetic Factors
The species barrier between cattle and humans appears to be incomplete, allowing BSE prions to infect humans. Genetic factors also play a role in susceptibility. Individuals
homozygous for methionine at codon 129 of the prion protein gene (PRNP) appear to be overrepresented among vCJD cases, suggesting that this polymorphism influences susceptibility
to infection[5].
vCJD is caused by the misfolding of normal cellular prion protein (PrP^C) into the pathogenic, protease-resistant isoform (PrP^Sc, or PrP^vCJD). The BSE/vCJD prion strain has distinct biochemical properties:
- Glycoform ratio: vCJD PrP^Sc has a characteristic type 4 Western blot pattern (non-glycosylated band at ~19 kDa) with a dominant diglycosylated band, distinct from sporadic CJD type 1 and type 2 patterns
- Strain identity: vCJD PrP^Sc is indistinguishable from BSE PrP^Sc in transmission studies, confirming the causal link
- Peripheral replication: Unlike sporadic CJD, the vCJD prion replicates extensively in lymphoreticular tissue (tonsils, spleen, lymph nodes, appendix, Peyer's patches) before invading the CNS. PrP^Sc is detectable in appendix tissue up to 2 years before neurological symptom onset.
- Neuroinvasion: Prions travel from the lymphoreticular system to the CNS via autonomic nerves (vagus nerve, sympathetic chain)
- CNS propagation: Within the brain, PrP^Sc propagates through a template-directed misfolding mechanism (prion-like spreading), causing:
- Spongiform vacuolar degeneration of [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and neuropil
- Extensive neuronal loss and gliosis
- Reactive astrogliosis
- Microglial activation
vCJD has distinctive neuropathological features:
- Florid plaques: Large, flower-like amyloid plaques composed of PrP^Sc surrounded by a halo of spongiform vacuolation — the pathological hallmark of vCJD (uncommon in other human prion diseases)
- Distribution: Florid plaques are most prominent in the [cerebral cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- and [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--
- Spongiform change: Widespread but particularly prominent in the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- (caudate and putamen) and posterior [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX-- ("pulvinar sign" on MRI)
- PrP immunostaining: Diffuse synaptic, perineuronal, and plaque-type PrP deposition throughout the brain
- No neurofibrillary tangles or Lewy bodies: Distinguishes from [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and Lewy Body Dementia
- PrP deposition in lymphoreticular tissues: Tonsil, spleen, lymph nodes
vCJD characteristically begins with psychiatric symptoms, often leading to initial psychiatric referral:
- Depression: Most common early symptom; often severe and treatment-resistant
- Anxiety: Generalized anxiety, panic attacks
- Social withdrawal and apathy: Loss of interest in activities, relationships
- Behavioral changes: Irritability, aggression, personality changes
- Psychotic features: Delusions, hallucinations (less common initially)
- Dysesthesias: Painful sensory symptoms (paresthesias, pain) in ~50% of patients; unusual for CJD
- Insomnia and sleep disturbances: Persistent sleep problems
Duration of psychiatric phase: typically 4–6 months before neurological signs emerge.
Early Stage (Weeks to Months):
- Persistent painful psychiatric symptoms, including depression, anxiety, and withdrawal
- Insomnia and sleep disturbances
- Unusual sensory symptoms, including dysesthesia (abnormal sensations)
- Cognitive difficulties
- Cerebellar ataxia: Progressive gait and limb ataxia — an early and prominent neurological feature
- Cognitive decline: Progressive dementia, eventually severe
- Movement disorders: Myoclonus (less prominent than in sporadic CJD), chorea, [dystonia[/diseases/[dystonia[/diseases/[dystonia[/diseases/[dystonia[/diseases/[dystonia--TEMP--/diseases)--FIX--
- Pyramidal signs: Spasticity, hyperreflexia, extensor plantar responses
- Sensory symptoms: Persistent painful dysesthesias
- Visual disturbances: Less common than in sporadic CJD
Middle Stage (Weeks to Months):
- Progressive cerebellar ataxia (loss of coordination)
- Chorea (involuntary movements)
- Myoclonus (muscle jerks)
- Cognitive decline and dementia
- Visual disturbances
- Akinetic mutism: Unresponsive state with minimal spontaneous movement or speech
- Complete dependence: Immobility, dysphagia, incontinence
- Median illness duration: ~14 months (range 6–40 months) — longer than sporadic CJD (~5 months)
[Late[/diseases/[late[/diseases/[late[/diseases/[late[/diseases/[late--TEMP--/diseases)--FIX-- Stage (Weeks to Months):
- Severe neurological impairment
- Akinetic mutism (inability to move or speak)
- Respiratory failure
- Death
The median duration from symptom onset to death is approximately 14 months, with a range of 6 to 39 months.
The classic triad of vCJD symptoms includes:
- Psychiatric/behavioral changes
- Cerebellar signs (ataxia)
- Cognitive decline/dementia
This triad, combined with the young age of onset, helps distinguish vCJD from sporadic CJD.
Diagnostic criteria were developed by the UK CJD Surveillance Unit:
Probable vCJD (in the absence of alternative diagnosis):
- Progressive neuropsychiatric disorder
- Duration >6 months
- Routine investigations do not suggest an alternative diagnosis
- No history of iatrogenic CJD exposure
- PLUS ≥4 of: early psychiatric symptoms, persistent painful sensory symptoms, ataxia, myoclonus/chorea/dystonia, dementia
Definite vCJD: Requires neuropathological confirmation (florid plaques, PrP^Sc immunostaining pattern)
vCJD is suspected based on clinical features and confirmed through neuropathological examination. The diagnostic criteria include:
- Progressive neuropsychiatric disorder
- Duration longer than 6 months
- Age at onset < 55 years (typical, but not absolute)
- Psychiatric symptoms at onset or early in course
- Characteristic MRI findings (see below)
- Positive tonsil biopsy (not routinely performed)
| Test |
Findings in vCJD |
| Brain MRI |
"Pulvinar sign": bilateral high signal in the posterior thalamus on FLAIR/DWI — present in >90% of cases and considered highly suggestive of vCJD. Also may show caudate and [putamen[/cell-types/[putamen[/cell-types/[putamen[/cell-types/[putamen[/cell-types/[putamen--TEMP--/cell-types)--FIX-- signal abnormalities. Less commonly, changes in the [caudate nucleus[/cell-types/[caudate-nucleus[/cell-types/[caudate-nucleus[/cell-types/[caudate-nucleus[/cell-types/[caudate-nucleus--TEMP--/cell-types)--FIX-- and putamen. |
| EEG |
Non-specific slowing; periodic sharp wave complexes (PSWCs) — characteristic of sporadic CJD — are typically absent in vCJD |
| CSF |
CSF 14-3-3 protein may be elevated but less sensitive than in sporadic CJD. Unlike sporadic CJD, vCJD typically shows normal 14-3-3 protein levels in cerebrospinal fluid, which can help differentiate it from sporadic CJD. RT-QuIC (real-time quaking-induced conversion) has high sensitivity for detecting prion seeding activity. |
| Tonsil biopsy |
Positive PrP^Sc immunostaining in lymphoid tissue — unique to vCJD among human prion diseases; can confirm diagnosis in life |
| Blood tests |
No routine blood test available. Novel blood-based prion detection assays (e.g., PMCA, RT-QuIC adapted for blood) under development. The Direct Detection Assay (DDA) can detect PrP^vCJD in blood. Recent studies have identified novel blood biomarkers that may aid in diagnosis. |
| Genetic testing |
PRNP codon 129 genotyping: all clinical cases to date have been MM |
Post-mortem examination reveals:
- Diffuse PrP amyloid plaques throughout the brain
- Spongiform change (vacuolation) in the cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, basal ganglia, and cerebellum
- Neuronal loss
- Astrocytosis (gliosis)
- PrP deposition in lymphoreticular tissues (tonsil, spleen, lymph nodes)
vCJD must be distinguished from:
- Sporadic CJD: Older age of onset, typical EEG findings, 14-3-3 positive CSF, rapid dementia, PSWCs on EEG, cortical ribboning on MRI
- Familial CJD: PRNP mutations
- Gerstmann-Sträussler-Scheinker syndrome (GSS): Autosomal dominant inheritance, longer disease duration
- Fatal familial insomnia (FFI): PRNP D178[19]N with 129M, predominant sleep disturbance, selective thalamic degeneration
- Psychiatric disorders: Depression, schizophrenia, bipolar disorder (early misdiagnosis is common)
- Frontotemporal Dementia: Behavioral changes, but typically older onset
- Autoimmune encephalitis: Treatable; antibody testing important
- Wilson's Disease: Treatable; copper studies, ceruloplasmin
- Other causes of early-onset dementia: [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, Frontotemporal Dementia
There is currently no effective treatment for vCJD. The disease is invariably fatal, and all [treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/treatments to date have been unsuccessful in altering disease progression. Current management focuses on supportive care and symptom relief.
- Symptomatic treatment: Medications for myoclonus (clonazepam, valproate), psychiatric symptoms (antidepressants, antipsychotics)
- Nutritional support: Dietary management, swallowing assessment
- Physical therapy: Maintaining mobility, preventing contractures
- Palliative care: Focus on quality of life
Several therapeutic approaches have been investigated:
- Quinacrine: Anti-malarial drug with anti-prion activity in vitro; no clinical benefit in trials
- Pentosan polysulfate (PPS): Intraventricular infusion via Ommaya reservoir; compassionate use in several patients showed possible prolongation of survival but no improvement in neurological function
- Doxycycline: Showed anti-prion properties in vitro; [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials failed to demonstrate benefit
- Anti-PrP antibodies: [Immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX-- targeting PrP^Sc is under preclinical investigation, including PRN100 (human anti-PrP monoclonal antibody), used in compassionate cases
- Anti-prion compounds: Novel small molecules targeting PrP^C to PrP^Sc conversion are in early-stage development
- Antisense oligonucleotides (ASOs): Targeting PRNP expression
- Immunotherapy: Antibodies against PrP^Sc
- Small molecule inhibitors: Compounds that prevent prion conversion
- Branched polyamines: Compounds that destabilize PrP^Sc aggregates
While promising in laboratory studies, none have shown efficacy in human trials to date.
- Palliative care is the mainstay of management
- Psychiatric symptom management (antidepressants, anxiolytics, antipsychotics)
- Seizure control (anticonvulsants)
- Pain management for dysesthesias (gabapentin, pregabalin, opioids)
- Nutritional support (PEG feeding when dysphagia develops)
- Psychosocial support for patients and families
- Physical therapy: Maintaining mobility, preventing contractures
The vCJD epidemic prompted unprecedented public health interventions:
¶ BSE Surveillance and Food Safety
- Bovine controls: BSE testing of cattle, bans on ruminant-derived animal feed, removal of specified risk materials from food chain
- Blood safety: Leukodepletion of all blood products in the UK (since 1999); deferral of UK residents from blood donation in many countries; importation of plasma from non-UK sources
- Surgical instrument decontamination: Enhanced prion decontamination protocols (autoclaving at 134°C for 18 minutes; use of disposable instruments for tonsillectomy and other procedures in contact with lymphoid tissue)
- Surveillance: National CJD surveillance programs in multiple countries
The emergence of vCJD led to significant changes in food safety regulations worldwide:
- Ban on specified risk materials (SRM) in human food
- Enhanced BSE surveillance in cattle
- Restrictions on cattle feed
- Blood donor deferral in affected countries
vCJD has been transmitted via blood transfusion in four documented cases in the UK, leading to permanent deferral of blood donors who have lived in BSE-affected countries. This iatrogenic transmission route highlights the importance of prion inactivation in blood products.
¶ Prevalence and Future Cases
The total number of vCJD cases is expected to remain relatively small due to effective food safety measures. However, the long incubation period (potentially decades) means that additional cases may continue to emerge. There is also concern about potential secondary transmission through blood products, surgical instruments, and the possibility of a fourth wave of cases in individuals with genetic susceptibility.
Current research areas include:
- Development of sensitive presymptomatic diagnostic tests
- Understanding the species barrier and transmission dynamics
- Identifying genetic modifiers of susceptibility
- Novel therapeutic approaches targeting prion protein conversion
- Surveillance for novel prion strains
- [prion disease[/diseases/[prion-disease[/diseases/[prion-disease[/diseases/[prion-disease[/diseases/[prion-disease--TEMP--/diseases)--FIX-- | Creutzfeldt-Jakob Disease
- [Fatal Familial Insomnia[/diseases/[fatal-familial-insomnia[/diseases/[fatal-familial-insomnia[/diseases/[fatal-familial-insomnia[/diseases/[fatal-familial-insomnia--TEMP--/diseases)--FIX-- | Gerstmann-Sträussler-Scheinker Disease
- [Kuru[/diseases/[kuru[/diseases/[kuru[/diseases/[kuru[/diseases/[kuru--TEMP--/diseases)--FIX-- | [Chronic Wasting Disease[/diseases/[chronic-wasting-disease[/diseases/[chronic-wasting-disease[/diseases/[chronic-wasting-disease[/diseases/[chronic-wasting-disease--TEMP--/diseases)--FIX--
- [Prion Protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein--TEMP--/proteins)--FIX-- | PRNP Gene
- [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX-- | [Protein Aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX--
- [Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases Index
- Creutzfeldt-Jakob Disease (CJD)
- Prion Disease
- Fatal Familial Insomnia (FFI)
- BSE (Bovine Spongiform Encephalopathy)
- PRNP Gene
- Prion-Like Spreading
The study of Variant [Creutzfeldt Jakob[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob--TEMP--/diseases)--FIX-- Disease (vCJD) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature. 1996;383(6602):685-690. PMID:11407401.
- Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob Disease in the UK. Lancet. 1996;347(9006):921-925. PMID:8907966.
- Watson N, Brandel JP, Green A, et al. The importance of ongoing surveillance for variant Creutzfeldt-Jakob Disease. Prion. 2016;10(1):6-15. PMID: PMC4815077.
- Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 1997;389(6650):498-501. PMID:11298251.
- Zeidler M, Ironside JW. The new variant of Creutzfeldt-Jakob Disease. Rev Neurol (Paris). 2000;156(6-7):531-536. PMID:11774078.
- Spencer MD, Knight RS, Will RG. First hundred cases of variant Creutzfeldt-Jakob Disease: retrospective case review. BMJ. 2002;324(7352):1479-1482. PMID: PMC2658798.
- Collie DA, Sellar RJ, Zeidler M, Colchester AC, Knight R, Will RJ. MRI of Creutzfeldt-Jakob Disease: imaging features and recommended MRI protocol. Clin Radiol. 2001;56(9):726-739. PMID:11474022.
- Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature. 1997;389(6650):448-450.
- Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob Disease using a highly sensitive immunoblotting assay. Lancet. 2001;358(9277):171-180.
- Ironside JW. Variant Creutzfeldt-Jakob Disease: an update. Folia Neuropathol. 2012;50(1):50-56. PMID:22505363.
- Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001;24:519-550.
- Gill ON, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ. 2013;347:f5675.
- Llewelyn CA, et al. Possible transmission of variant Creutzfeldt-Jakob Disease by blood transfusion. Lancet. 2004;363(9407):417-421.
- Spencer MD, et al. Voxel-based morphometry of the brains of patients with variant and sporadic forms of CJD. NeuroImage. 2002;17(4):1694-1700.
- Zeidler M, et al. New variant Creutzfeldt-Jakob Disease: psychiatric features. Lancet. 1997;350(9082):908-910.
- Heath CA, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob Disease. Ann Neurol. 2010;67(6):761-770.
- Mead S, et al. A novel Prion Disease associated with diarrhea and autonomic neuropathy. N Engl J Med. 2013;369(20):1904-1914.
- Collinge J, et al. Kuru in the 21st century — an acquired human Prion Disease with very long incubation periods. Lancet. 2006;367(9528):2068-2074.
- National CJD Research & Surveillance Unit. CJD Statistics. Updated 2024.
- Concha-Marambio L, et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob Disease. Sci Transl Med. 2016;8(370):370ra183.